Device therapy in Chagas disease heart failure

References

• Anonymous. Chagas disease (American Trypanosomiasis) fact sheet. Wkly Epidemiol. Rec. 85, 334–336 (2010).
   PubMedGoogle Scholar
• Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem. Inst. Oswaldo Cruz 102(Suppl. 1), 75–85 (2007).
   PubMed Web of Science ®Google Scholar
• Laranja FS, Dias E, Miranda A, Nobrega G. Chagas’ disease; a clinical, epidemiologic, and pathologic study. Circulation 14(6), 1035–1060 (1956).
   PubMed Web of Science ®Google Scholar
• Bestetti RB, Theodoropoulos TA, Cardinalli-Neto A, Cury PM. Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy. Am. Heart J. 156(3), 422–430 (2008).
   PubMedGoogle Scholar
• Bestetti RB, Freitas OC, Muccillo G, Oliveira JS. Clinical and morphological characteristics associated with sudden cardiac death in patients with Chagas’ disease. Eur. Heart J. 14(12), 1610–1614 (1993).
   PubMedGoogle Scholar
• Manzullo EC, Chuit R. Risk of death due to chronic chagasic cardiopathy. Mem. Inst. Oswaldo Cruz 94(Suppl. 1), 317–320 (1999).
   PubMed Web of Science ®Google Scholar
• Bestetti RB, Dalbo CM, Arruda CA, Correia Filho D, Freitas OC. Predictors of sudden cardiac death for patients with Chagas’ disease: a hospital-derived cohort study. Cardiology 87(6), 481–487 (1996).
   PubMedGoogle Scholar
• Salles G, Xavier S, Sousa A, Hasslocher-Moreno A, Cardoso C. Prognostic value of QT interval parameters for mortality risk stratification in Chagas’ disease: results of a long-term follow-up study. Circulation 108(3), 305–312 (2003).
   PubMed Web of Science ®Google Scholar
• Bestetti RB, Cardinalli-Neto A. Sudden cardiac death in Chagas’ heart disease in the contemporary era. Int. J. Cardiol. 131(1), 9–17 (2008).
   PubMedGoogle Scholar
• Cardinalli-Neto A, Greco OT, Bestetti RB. Automatic implantable cardioverter–defibrillators in Chagas’ heart disease patients with malignant ventricular arrhythmias. Pacing Clin. Electrophysiol. 29(5), 467–470 (2006).
   PubMedGoogle Scholar
• Bestetti RB, Muccillo G. Clinical course of Chagas’ heart disease: a comparison with dilated cardiomyopathy. Int. J. Cardiol. 60(2), 187–193 (1997).
   PubMed Web of Science ®Google Scholar
• Valdigem BP, Pereira FB, da Silva NJ et al. Ablation of ventricular tachycardia in chronic chagasic cardiomyopathy with giant basal aneurysm: Carto sound, CT, and MRI merge. Circ. Arrhythm. Electrophysiol. 4(1), 112–114 (2011).
   PubMedGoogle Scholar
• Milei J, Pesce R, Valero E, Muratore C, Beigelman R, Ferrans VJ. Electrophysiologic-structural correlations in chagasic aneurysms causing malignant arrhythmias. Int. J. Cardiol. 32(1), 65–73 (1991).
   PubMedGoogle Scholar
• Henz BD, do Nascimento TA, Dietrich Cde O et al. Simultaneous epicardial and endocardial substrate mapping and radiofrequency catheter ablation as first-line treatment for ventricular tachycardia and frequent ICD shocks in chronic chagasic cardiomyopathy. J. Interv. Card. Electrophysiol. 26(3), 195–205 (2009).
   PubMedGoogle Scholar
• Bestetti RB, Santos CR, Machado-Júnior OB et al. Clinical profile of patients with Chagas’ disease before and during sustained ventricular tachycardia. Int. J. Cardiol. 29(1), 39–46 (1990).
   PubMedGoogle Scholar
• Viotti R, Vigliano C, Lococo B et al. Clinical predictors of chronic chagasic myocarditis progression. Rev. Esp. Cardiol. 58(9), 1037–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Leite LR, Fenelon G, Simoes A Jr, Silva GG, Friedman PA, de Paola AA. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. J. Cardiovasc. Electrophysiol. 14(6), 567–573 (2003).
   PubMedGoogle Scholar
• Silva RM, Távora MZ, Gondim FA, Metha N, Hara VM, Paola AA. Predictive value of clinical and electrophysiological variables in patients with chronic chagasic cardiomyopathy and nonsustained ventricular tachycardia. Arq. Bras. Cardiol. 75(1), 33–47 (2000).
   PubMedGoogle Scholar
• Bertolino ND, Villafanha DF, Cardinalli-Neto A et al. Prognostic impact of Chagas’ disease in patients awaiting heart transplantation. J. Heart Lung Transplant. 29(4), 449–453 (2010).
   PubMedGoogle Scholar
• Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas’ heart disease. Int. J. Cardiol. 102(2), 239–247 (2005).
   PubMed Web of Science ®Google Scholar
• Theodoropoulos TA, Bestetti RB, Otaviano AP, Cordeiro JA, Rodrigues VC, Silva AC. Predictors of all-cause mortality in chronic Chagas’ heart disease in the current era of heart failure therapy. Int. J. Cardiol. 128(1), 22–29 (2008).
   PubMedGoogle Scholar
• Pereira Nunes Mdo C, Barbosa MM, Ribeiro AL, Amorim Fenelon LM, Rocha MO. Predictors of mortality in patients with dilated cardiomyopathy: relevance of chagas disease as an etiological factor. Rev. Esp. Cardiol. 63(7), 788–797 (2010).
   PubMedGoogle Scholar
• Barbosa AP, Cardinalli Neto A, Otaviano AP, Rocha BF, Bestetti RB. Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy. Arq. Bras. Cardiol. 97(6), 517–525 (2011).
   PubMedGoogle Scholar
• Vilas Boas LG, Bestetti RB, Otaviano AP, Cardinalli-Neto A, Nogueira PR. Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.01.033 (2012) (Epub ahead of print).
   Google Scholar
• Veiga MF, Rodrigues IF, Cardinalli-Neto A, Otaviano AP, da Rocha BF, Bestetti RB. Clinical course of patients with chronic systolic heart failure due to the association of Chagas disease and systemic arterial hypertension. Int. J. Cardiol. 149(1), 122–124 (2011).
   PubMedGoogle Scholar
• Oliveira JS, Mello De Oliveira JA, Frederigue U Jr, Lima Filho EC. Apical aneurysm of Chagas’s heart disease. Br. Heart J. 46(4), 432–437 (1981).
   PubMedGoogle Scholar
• Samuel J, Oliveira M, Correa De Araujo RR, Navarro MA, Muccillo G. Cardiac thrombosis and thromboembolism in chronic Chagas’ heart disease. Am. J. Cardiol. 52(1), 147–151 (1983).
   PubMedGoogle Scholar
• Mocelin AO, Issa VS, Bacal F, Guimarães GV, Cunha E, Bocchi EA. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas’ heart disease and idiopathic dilated cardiomyopathy. Eur. J. Heart Fail. 7(5), 869–873 (2005).
   PubMedGoogle Scholar
• Rossi MA, Ramos SG, Bestetti RB. Chagas’ heart disease: clinical-pathological correlation. Front. Biosci. 8, e94–e109 (2003).
   PubMed Web of Science ®Google Scholar
• Bellotti G, Bocchi EA, de Moraes AV et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am. Heart J. 131(2), 301–307 (1996).
   PubMedGoogle Scholar
• Bestetti RB, Coutinho-Netto J, Staibano L, Pinto LZ, Muccillo G, Oliveira JS. Peripheral and coronary sinus catecholamine levels in patients with severe congestive heart failure due to Chagas’ disease. Cardiology 86(3), 202–206 (1995).
   PubMedGoogle Scholar
• Bellabarba G, Davila DF, Torres A et al. Plasma renin activity in chagasic patients with and without congestive heart failure. Int. J. Cardiol. 47(1), 5–11 (1994).
   PubMedGoogle Scholar
• Ribeiro AL, Moraes RS, Ribeiro JP et al. Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. Am. Heart J. 141(2), 260–265 (2001).
   PubMed Web of Science ®Google Scholar
• Gerbi FC, Takahashi JT, Cardinalli-Neto A, Nogueira PR, Bestetti RB. Heart rate variability in the frequency domain in chronic Chagas disease: correlation of autonomic dysfunction with variables of daily clinical practice. Int. J. Cardiol. 150(3), 357–358 (2011).
   PubMedGoogle Scholar
• Guzzetti S, Iosa D, Pecis M, Bonura L, Prosdocimi M, Malliani A. Impaired heart rate variability in patients with chronic Chagas’ disease. Am. Heart J. 121(6 Pt 1), 1727–1734 (1991).
   PubMed Web of Science ®Google Scholar
• Simões MV, Pintya AO, Bromberg-Marin G et al. Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas’ cardiomyopathy. Am. J. Cardiol. 86(9), 975–981 (2000).
   PubMedGoogle Scholar
• Bestetti RB, Sales-Neto VN, Pinto LZ, Soares EG, Muccillo G, Oliveira JS. Effects of long term metoprolol administration on the electrocardiogram of rats infected with T. cruzi. Cardiovasc. Res. 24(7), 521–527 (1990).
   PubMedGoogle Scholar
• Dávila DF, Angel F, Arata de Bellabarba G, Donis JH. Effects of metoprolol in chagasic patients with severe congestive heart failure. Int. J. Cardiol. 85(2–3), 255–260 (2002).
   PubMedGoogle Scholar
• Issa VS, Amaral AF, Cruz FD et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ. Heart Fail. 3(1), 82–88 (2010).
   PubMed Web of Science ®Google Scholar
• Bestetti RB, Otaviano AP, Cardinalli-Neto A, da Rocha BF, Theodoropoulos TA, Cordeiro JA. Effects of b-Blockers on outcome of patients with Chagas’ cardiomyopathy with chronic heart failure. Int. J. Cardiol. 151(2), 205–208 (2011).
   PubMed Web of Science ®Google Scholar
• Willenheimer R, van Veldhuisen DJ, Silke B et al.; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112(16), 2426–2435 (2005).
   PubMed Web of Science ®Google Scholar
• Bestetti RB, Theodoropoulos TA. A systematic review of studies on heart transplantation for patients with end-stage Chagas’ heart disease. J. Card. Fail. 15(3), 249–255 (2009).
   PubMedGoogle Scholar
• Bristow MR, Saxon LA, Boehmer J et al.; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350(21), 2140–2150 (2004).
   PubMed Web of Science ®Google Scholar
• Carson P, Anand I, O’Connor C et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J. Am. Coll. Cardiol. 46(12), 2329–2334 (2005).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E et al.; Cardiac Resynchronization–Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352(15), 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J. Am. Coll. Cardiol. 52(23), 1834–1843 (2008).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS et al.; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 361(14), 1329–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Tang AS, Wells GA, Talajic M et al.; Resynchronization–Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med. 363(25), 2385–2395 (2010).
   PubMed Web of Science ®Google Scholar
• Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann. Intern. Med. 154(6), 401–412 (2011).
   PubMed Web of Science ®Google Scholar
• Duarte O, Magalhães LP, Santana OO et al. Prevalence and prognostic value of ventricular dyssynchrony in Chagas cardiomyopathy. Arq. Bras. Cardiol. 96(4), 300–306 (2011).
   PubMedGoogle Scholar
• Hauptman PJ, Swindle JP, Masoudi FA, Burroughs TE. Underutilization of beta-blockers in patients undergoing implantable cardioverter–defibrillator and cardiac resynchronization procedures. Circ. Cardiovasc. Qual. Outcomes 3(2), 204–211 (2010).
   PubMedGoogle Scholar
• Menezes AS. Outcome of right ventricular bifocal pacing in patients with permanent atrial fibrillation and severe dilated cardiomyopathy due to Chagas disease. J. Interv. Card. Electrophysiol. 11(3), 193–198 (2004).
   PubMedGoogle Scholar
• Silva RT, Martinelli Filho M, Lima CE et al. Functional behavior of patients with conventional pacemakers undergoing cardiac resynchronization. Arq. Bras. Cardiol. 90(2), 138–143 (2008).
   PubMedGoogle Scholar
• Muratore CA, Batista Sa LA, Chiale PA et al. Implantable cardioverter defibrillators and Chagas’ disease: results of the ICD Registry Latin America. Europace 11(2), 164–168 (2009).
   PubMedGoogle Scholar
• di Toro D, Muratore C, Aguinaga L et al. Predictors of all-cause 1-year mortality in implantable cardioverter defibrillator patients with chronic Chagas’ cardiomyopathy. Pacing Clin. Electrophysiol. 34(9), 1063–1069 (2011).
   PubMedGoogle Scholar
• Cardinalli-Neto A, Nakazone MA, Grassi LV, Tavares BG, Bestetti RB. Implantable Cardioverter–defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy. Int. J. Cardiol. 150(1), 94–95 (2011).
   PubMedGoogle Scholar
• Bestetti RB, Dalbo CM, Freitas OC, Teno LA, Castilho OT, Oliveira JS. Noninvasive predictors of mortality for patients with Chagas’ heart disease: a multivariate stepwise logistic regression study. Cardiology 84(4–5), 261–267 (1994).
   PubMedGoogle Scholar
• Carrasco HA, Parada H, Guerrero L, Duque M, Durán D, Molina C. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas’ disease. Int. J. Cardiol. 43(1), 27–38 (1994).
   PubMedGoogle Scholar
• Rabinovich R, Muratore C, Iglesias R et al. Time to first shock in implantable cardioverter defibrillator (ICD) patients with Chagas cardiomyopathy. Pacing Clin. Electrophysiol. 22(1 Pt 2), 202–205 (1999).
   PubMedGoogle Scholar
• Martinelli-Filho M, De Siqueira SF, Moreira H et al. Probability of occurrence of life-threatening ventricular arrhythmias in Chagas’ disease versus non-Chagas’ disease. Pacing Clin. Electrophysiol. 23(11 Pt 2), 1944–1946 (2000).
   PubMedGoogle Scholar
• Cardinalli-Neto A, Greco OT, Bestetti RB. Automatic implantable Cardioverter–defibrillators in Chagas’ heart disease patients with malignant ventricular arrhythmias. Pacing Clin. Electrophysiol. 29, 467–470 (2006).
   PubMed Web of Science ®Google Scholar
• Cardinalli-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of all-cause mortality for patients with chronic Chagas’ heart disease receiving implantable cardioverter defibrillator therapy. J. Cardiovasc. Electrophysiol. 18(12), 1236–1240 (2007).
   PubMedGoogle Scholar
• Manzano-Fernández S, Saura D, Pastor P, Pastor FJ, Morena Gde L, Valdés-Chavarri M. Ventricular arrhythmias in chronic Chagas’ myocardiopathy: a case report and brief review of different antiarrhythmic strategies. Int. J. Cardiol. 138(1), 88–90 (2010).
   PubMedGoogle Scholar
• Flores-Ocampo J, Nava S, Márquez MF et al. [Clinical predictors of ventricular arrhythmia storms in Chagas cardiomyopathy patients with implantable defibrillators]. Arch. Cardiol. Mex. 79(4), 263–267 (2009).
   PubMedGoogle Scholar
• Verma A, Sarak B, Kaplan AJ et al. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy. Pacing Clin. Electrophysiol. 33(3), 320–329 (2010).
   PubMed Web of Science ®Google Scholar
• Andrade JÁ, Marin-Neto JÁ, Paola AAV et al. Sociedade Brasileira de Cardiologia. I Diretriz Latino-Americana para o diagnóstico e tratamento da Cardiopatia Chagásica. Arq Bras Cardiol. 97(2 Suppl. 3), 1–48, (2011).
   PubMedGoogle Scholar
• Scanavacca MI, Sosa EA, Lee JH, Bellotti G, Pileggi F. Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia. Arq. Bras. Cardiol. 54(6), 367–371 (1990).
   PubMedGoogle Scholar
• Bertoldi EG, Rohde LE, Zimerman LI, Pimentel M, Polanczyk CA. Cost effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country’s public health system. Int. J. Cardiol. doi:10.1016/j.ijcard.2011.06.046 (2011) (Epub ahead of print).
   PubMedGoogle Scholar